{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:33:48Z","timestamp":1767652428590,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"genulf"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00345-021-03850-y","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:54:49Z","timestamp":1633874089000},"page":"489-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6811","authenticated-orcid":false,"given":"Geoffroy","family":"de Sallmard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Aim\u00e9e","family":"Perrouin-Verbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Biardeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Maucort-Boulch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Chartier-Kastler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Ph\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Even","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Joussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e8s","family":"Dominique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Saussine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"3850_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/aje\/kwm356","volume":"167","author":"SL Tennstedt","year":"2008","unstructured":"Tennstedt SL, Link CL, Steers WD, McKinlay JB (2008) Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey. Am J Epidemiol 167:390\u2013399. https:\/\/doi.org\/10.1093\/aje\/kwm356","journal-title":"Am J Epidemiol"},{"key":"3850_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/nau.23331","volume":"37","author":"JTN Tamanini","year":"2018","unstructured":"Tamanini JTN, Pallone LV, Sartori MGF et al (2018) A populational\u2014based survey on the prevalence, incidence, and risk factors of urinary incontinence in older adults\u2014results from the \u201cSABE STUDY.\u201d Neurourol Urodyn 37:466\u2013477. https:\/\/doi.org\/10.1002\/nau.23331","journal-title":"Neurourol Urodyn"},{"key":"3850_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2006.10.062","volume":"177","author":"HH Lai","year":"2007","unstructured":"Lai HH, Hsu EI, Teh BS et al (2007) 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. J Urol 177:1021\u20131025. https:\/\/doi.org\/10.1016\/j.juro.2006.10.062","journal-title":"J Urol"},{"key":"3850_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.urology.2017.09.025","volume":"113","author":"KD Radadia","year":"2018","unstructured":"Radadia KD, Farber NJ, Shinder B et al (2018) Management of postradical prostatectomy urinary incontinence: a review. Urology 113:13\u201319. https:\/\/doi.org\/10.1016\/j.urology.2017.09.025","journal-title":"Urology"},{"key":"3850_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1002\/nau.22989","volume":"35","author":"X Biardeau","year":"2016","unstructured":"Biardeau X, Aharony S, Campeau L, Corcos J (2016) Artificial urinary sphincter: report of the 2015 consensus conference. Neurourol Urodyn 35:S8\u2013S24. https:\/\/doi.org\/10.1002\/nau.22989","journal-title":"Neurourol Urodyn"},{"key":"3850_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.urology.2006.10.026","volume":"69","author":"DD Thiel","year":"2007","unstructured":"Thiel DD, Young PR, Broderick GA et al (2007) Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology 69:315\u2013319. https:\/\/doi.org\/10.1016\/j.urology.2006.10.026","journal-title":"Urology"},{"key":"3850_CR7","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/nau.24378","volume":"39","author":"MS Jahromi","year":"2020","unstructured":"Jahromi MS, Engle K, Furlong D et al (2020) Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement. Neurourol Urodyn 39:1489\u20131493. https:\/\/doi.org\/10.1002\/nau.24378","journal-title":"Neurourol Urodyn"},{"key":"3850_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.urology.2017.09.027","volume":"113","author":"KJ Ko","year":"2018","unstructured":"Ko KJ, Lee CU, Kim TH et al (2018) Predictive factors of de novo overactive bladder after artificial urinary sphincter implantation in men with postprostatectomy incontinence. Urology 113:215\u2013219. https:\/\/doi.org\/10.1016\/j.urology.2017.09.027","journal-title":"Urology"},{"key":"3850_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.juro.2011.02.021","volume":"185","author":"HH Lai","year":"2011","unstructured":"Lai HH, Boone TB (2011) Implantation of artificial urinary sphincter in patients with post-prostatectomy incontinence, and preoperative overactive bladder and mixed symptoms. J Urol 185:2254\u20132259. https:\/\/doi.org\/10.1016\/j.juro.2011.02.021","journal-title":"J Urol"},{"key":"3850_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/JU.0000000000000314","volume":"202","author":"JS Sandhu","year":"2019","unstructured":"Sandhu JS, Benjamin B, Craig C et al (2019) Incontinence after prostate treatment: AUA\/SUFU guideline. J Urol 202:369\u2013378. https:\/\/doi.org\/10.1097\/JU.0000000000000314","journal-title":"J Urol"},{"key":"3850_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bju.12207","volume":"112","author":"E Chung","year":"2013","unstructured":"Chung E, Cartmill R (2013) Diagnostic challenges in the evaluation of persistent or recurrent urinary incontinence after artificial urinary sphincter (AUS) implantation in patients after prostatectomy. BJU Int 112:32\u201335. https:\/\/doi.org\/10.1111\/bju.12207","journal-title":"BJU Int"},{"key":"3850_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","volume":"73","author":"AK Nambiar","year":"2018","unstructured":"Nambiar AK, Bosch R, Cruz F et al (2018) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 73:596\u2013609. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.031","journal-title":"Eur Urol"},{"key":"3850_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/01.ju.0000132151.53532.86","volume":"172","author":"M Roupret","year":"2004","unstructured":"Roupret M, Chartier-Kastler E, Almeras C et al (2004) Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter. J Urol 172:236\u2013239. https:\/\/doi.org\/10.1097\/01.ju.0000132151.53532.86","journal-title":"J Urol"},{"key":"3850_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100\u2013119. https:\/\/doi.org\/10.1016\/j.eururo.2008.09.009","journal-title":"Eur Urol"},{"key":"3850_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","volume":"62","author":"DG Tincello","year":"2012","unstructured":"Tincello DG, Kenyon S, Abrams KR et al (2012) Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 62:507\u2013514. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.056","journal-title":"Eur Urol"},{"key":"3850_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/nau.22598","volume":"34","author":"Y Cui","year":"2015","unstructured":"Cui Y, Zhou X, Zong H et al (2015) The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn 34:413\u2013419. https:\/\/doi.org\/10.1002\/nau.22598","journal-title":"Neurourol Urodyn"},{"key":"3850_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11934-018-0847-3","volume":"19","author":"B Peyronnet","year":"2018","unstructured":"Peyronnet B, Brucker BM (2018) Management of overactive bladder symptoms after radical prostatectomy. Curr Urol Rep 19:95. https:\/\/doi.org\/10.1007\/s11934-018-0847-3","journal-title":"Curr Urol Rep"},{"issue":"Suppl 3","key":"3850_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.13110","volume":"116","author":"D Habashy","year":"2015","unstructured":"Habashy D, Losco G, Tse V et al (2015) Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int 116(Suppl 3):61\u201365. https:\/\/doi.org\/10.1111\/bju.13110","journal-title":"BJU Int"},{"key":"3850_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE et al (2012) Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med 367:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1208872","journal-title":"N Engl J Med"},{"key":"3850_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/bju.13945","volume":"120","author":"MJ Drake","year":"2017","unstructured":"Drake MJ, Nitti VW, Ginsberg DA et al (2017) Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 120:611\u2013622. https:\/\/doi.org\/10.1111\/bju.13945","journal-title":"BJU Int"},{"key":"3850_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.02.005","volume":"127","author":"G Lozano-Ortega","year":"2019","unstructured":"Lozano-Ortega G, Walker D, Rogula B et al (2019) The relative efficacy and safety of mirabegron and onabotulinumtoxina in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis. Urology 127:1\u20138. https:\/\/doi.org\/10.1016\/j.urology.2019.02.005","journal-title":"Urology"},{"key":"3850_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","volume":"201","author":"M Baron","year":"2019","unstructured":"Baron M, Peyronnet B, Aubl\u00e9 A et al (2019) Long-term discontinuation of botulinum toxin a intradetrusor injections for neurogenic detrusor overactivity: a multicenter study. J Urol 201:769\u2013776. https:\/\/doi.org\/10.1016\/j.juro.2018.10.012","journal-title":"J Urol"},{"key":"3850_CR23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/nau.24326","volume":"39","author":"M Baron","year":"2020","unstructured":"Baron M, Perrouin-Verbe M-A, Lacombe S et al (2020) Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder. Neurourol Urodyn 39:1012\u20131019. https:\/\/doi.org\/10.1002\/nau.24326","journal-title":"Neurourol Urodyn"},{"key":"3850_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jpurol.2006.06.005","volume":"2","author":"L Mazzone","year":"2006","unstructured":"Mazzone L, Weber D, van der Hoeff M et al (2006) Hazard of botulinum toxin type A injection into the detrusor in patients with an artificial urinary sphincter. J Pediatr Urol 2:399\u2013401. https:\/\/doi.org\/10.1016\/j.jpurol.2006.06.005","journal-title":"J Pediatr Urol"},{"key":"3850_CR25","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/nau.24158","volume":"38","author":"A Kasman","year":"2019","unstructured":"Kasman A, Stave C, Elliott CS (2019) Combination therapy in overactive bladder-untapped research opportunities: a systematic review of the literature. Neurourol Urodyn 38:2083\u20132092. https:\/\/doi.org\/10.1002\/nau.24158","journal-title":"Neurourol Urodyn"},{"key":"3850_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.eururo.2012.03.008","volume":"63","author":"P Costa","year":"2013","unstructured":"Costa P, Poinas G, Ben Naoum K et al (2013) Long-term results of artificial urinary sphincter for women with type III stress urinary incontinence. Eur Urol 63:753\u2013758. https:\/\/doi.org\/10.1016\/j.eururo.2012.03.008","journal-title":"Eur Urol"},{"key":"3850_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/aja.aja_128_19","volume":"22","author":"E Chung","year":"2020","unstructured":"Chung E (2020) Artificial urinary sphincter surgery in the special populations: neurological, revision, concurrent penile prosthesis and female stress urinary incontinence groups. Asian J Androl 22:45\u201350. https:\/\/doi.org\/10.4103\/aja.aja_128_19","journal-title":"Asian J Androl"},{"key":"3850_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.21037\/tau.2019.08.02","volume":"9","author":"TC Boswell","year":"2020","unstructured":"Boswell TC, Elliott DS, Rangel LJ, Linder BJ (2020) Long-term device survival and quality of life outcomes following artificial urinary sphincter placement. Transl Androl Urol 9:56\u201361. https:\/\/doi.org\/10.21037\/tau.2019.08.02","journal-title":"Transl Androl Urol"},{"key":"3850_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/nau.23364","volume":"37","author":"SHM Reuvers","year":"2018","unstructured":"Reuvers SHM, Groen J, Scheepe JR et al (2018) Heterogeneity in reporting on urinary outcome and cure after surgical interventions for stress urinary incontinence in adult neuro-urological patients: a systematic review. Neurourol Urodyn 37:554\u2013565. https:\/\/doi.org\/10.1002\/nau.23364","journal-title":"Neurourol Urodyn"},{"key":"3850_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00345-015-1666-5","volume":"34","author":"B Peyronnet","year":"2016","unstructured":"Peyronnet B, Roumigui\u00e9 M, Castel-Lacanal E et al (2016) Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol 34:755\u2013761. https:\/\/doi.org\/10.1007\/s00345-015-1666-5","journal-title":"World J Urol"},{"key":"3850_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/nau.23884","volume":"38","author":"D de Bezerra S\u00e1 Dantas","year":"2019","unstructured":"de Bezerra S\u00e1 Dantas D, de Toledo LGM, da Carram\u00e3o Silva S et al (2019) A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder. Neurourol Urodyn 38:660\u2013667. https:\/\/doi.org\/10.1002\/nau.23884","journal-title":"Neurourol Urodyn"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:59:05Z","timestamp":1651208345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3850"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03850-y","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E. Chartier-Kastler: consultant and\/or investigator and\/or invited speaker for Medtronic, Axonics, Allergan, Coloplast, B Braun, ConvaTec, Pierre Fabre M\u00e9dicaments, Astellas, Promedon, UroMems, Boston Scientific. A. Ruffion: consultant, investigator, speaker for Teleflex, Astellas, Axonics, Medtronic, Allergan; Investigator and speaker for Ipsen, Boston Scientific, Tajeda, Steba, Janssen, AFU committee member, President of \u201cColl\u00e8ge Fran\u00e7ais des Urologues\u201d, Chief Urology Lyon Sud, DHU Lyon. X. Biardeau, speaker for Medtronic, Boston Scientific, Coloplast. X. Gam\u00e9: consultant Pierre Fabre, Medtronic, Coloplast, Teleflex, Hollister, Mylan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}